NEXTBio Capital Management LP Invests $6.04 Million in Inventiva S.A. Sponsored ADR $IVA

NEXTBio Capital Management LP purchased a new stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,298,701 shares of the company’s stock, valued at approximately $6,039,000. Inventiva comprises 3.5% of NEXTBio Capital Management LP’s portfolio, making the stock its 11th biggest position. NEXTBio Capital Management LP owned 0.89% of Inventiva at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. UBS Group AG grew its holdings in Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after purchasing an additional 2,634,580 shares during the period. SymBiosis Capital Partners LLC bought a new stake in Inventiva in the fourth quarter valued at approximately $12,090,000. Franklin Resources Inc. bought a new stake in Inventiva in the fourth quarter valued at approximately $11,626,000. Propel Bio Management LLC bought a new stake in Inventiva in the fourth quarter valued at approximately $4,650,000. Finally, Alyeska Investment Group L.P. bought a new stake in Inventiva in the fourth quarter valued at approximately $2,325,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Price Performance

NASDAQ IVA opened at $3.85 on Friday. The business has a 50 day simple moving average of $5.07 and a 200 day simple moving average of $5.39. Inventiva S.A. Sponsored ADR has a 52-week low of $2.85 and a 52-week high of $7.98.

Inventiva (NASDAQ:IVA) last posted its earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share (EPS) for the quarter. The company had revenue of $0.01 million during the quarter. Equities analysts expect that Inventiva S.A. Sponsored ADR will post -0.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on IVA shares. Wall Street Zen downgraded shares of Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Truist Financial started coverage on shares of Inventiva in a research note on Thursday, March 19th. They issued a “buy” rating and a $13.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $16.56.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.